Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales

Novavax, Inc. shares are on a dream run this year amid catalysts including its COVID-19 vaccine program.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.